Corvus Pharmaceuticals (CRVS) Equity Average (2016 - 2026)

Corvus Pharmaceuticals' Equity Average history runs 11 years deep, the most recent figure standing at $150.9 million for Q1 2026.

• In Q1 2026, Equity Average rose 268.63% year-over-year to $150.9 million; the TTM figure through Mar 2026 stood at $150.9 million (up 268.63% YoY), while the FY2025 annual figure was $46.9 million, up 31.61% from the prior year.
• Equity Average was $150.9 million for Q1 2026 at Corvus Pharmaceuticals, up from $66.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $150.9 million in Q1 2026 to a low of $22.5 million in Q4 2024.
• Historically, Equity Average has averaged $60.8 million across 5 years, with a median of $52.5 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Equity Average plunged 45.79% in 2024, then surged 268.63% in 2026.
• A 5-year view of Equity Average shows it stood at $60.4 million in 2022, then sank by 31.31% to $41.5 million in 2023, then slumped by 45.79% to $22.5 million in 2024, then soared by 195.65% to $66.5 million in 2025, then jumped by 127.03% to $150.9 million in 2026.
• The last three Equity Average figures came in at $150.9 million (Q1 2026), $66.5 million (Q4 2025), and $76.0 million (Q3 2025), per Business Quant data.